Live attenuated virus vaccines for la crosse virus and other bunyaviridae
US9884104B2 · kind B2 · utility
3Cited by
1References
9Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Feb 8, 2016 |
| Grant date | Feb 6, 2018 |
| Priority date | — |
| Expiry date | Feb 8, 2036 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2760/12034
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention relates to vaccine compositions including CEV serogroup immunogens, attenuated and inactivated viruses of the CEV serogroup and chimeric Bunyaviridae. Also disclosed are methods of treating or preventing CEV serogroup infection in a mammalian host, methods of producing a subunit vaccine composition or an immunogenic composition, isolated polynucleotides comprising a nucleotide sequence encoding a CEV serogroup immunogen, methods for detecting La Crosse virus (LACY) infection in a biological sample and infectious chimeric Bunyaviridae.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.